Buy Pfizer India; target of Rs 4800: Anand Rathi

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Anand Rathi's research report on Pfizer India

Pfizer’s Q3 revenue slid 8% y/y, 3% q/q, to Rs6.2bn. Even as MinipressXL growth was good, Becosules was flat, while Mucaine, Gelusil and Wysolone declined. The gross margins was steady q/q at 65%. Sequentially, staff costs and other expenses were up 11% each, which led to a 360bp contraction in the EBITDA margin to 32.7%. PAT was Rs1.5bn (up 5% y/y). Management had earlier said in the AGM, that FY23 is expected to be soft (on a high base), while we believe FY24/FY25 revenues should pick up.

Outlook

We retain our Buy, at a lower TP of Rs4,800 (earlier Rs5,225), at 32x FY25e EPS.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Pfizer India - 14 -02 - 2023 - anand